Page 7 - Code Therapeutics News Today

TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 27,100 shares, a growth of 22.1% from the May 15th total of 22,200 shares. Based on an average daily trading volume, of 162,200 shares, the days-to-cover ratio […]

TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) CEO Robert Michael Dudley purchased 19,000 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The stock was acquired at an average price of $2.76 per share, with a total value of $52,440.00. Following the completion of the purchase, the chief executive officer […]

TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) CEO Robert Michael Dudley bought 19,000 shares of the stock in a transaction on Friday, June 9th. The shares were acquired at an average cost of $2.76 per share, for a total transaction of $52,440.00. Following the acquisition, the chief executive officer now directly owns 912,114 shares in […]

Newark, New Castle, USA, June 06, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global CFTR correctors/modulators market was conducted by Growth...

FinancialContent fully hosted finance channel

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Angèle Maki, Ph.D., Senior Vice President, Business Development of ReCode Therapeutics, will present a company overview a...

Terns Pharmaceuticals (NASDAQ:TERN – Get Rating) and TransCode Therapeutics (NASDAQ:RNAZ – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation. Insider and Institutional Ownership 15.9% of TransCode Therapeutics shares […]

Gainers Clearmind Medicine Inc. (NASDAQ:CMND) gained 61.5% to $0.88 in pre-market trading after dropping around 3% on Tuesday. Clearmind engaged...

– Renowned physician-scientist brings deep expertise in clinical development and inhaled drug delivery to ReCode as lead programs for primary ciliary dyskinesia and cystic fibrosis enter clinical trials –MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using superi...

BOSTON, April 06, 2023 -- TransCode Therapeutics, Inc. , the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it will... | April 6, 2023